Journals / European Journal of Breast Health / 2018 / Cilt: 14 - Sayı: 2

Biological Subtypes of Breast Cancer and Sentinel Lymph Node Biopsy

Pages
100–104
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results of biological tumor characteristics and characteristicsof the patients on different SLN biopsy techniques were investigated.Results: The overall SLN detecting success rate was 83.3%.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:ABSTRACTObjective: Breast cancer subtypes are used as prognostic and predictive factors considering the genomic profile of the disease.
📊
Key Findings & Data:This study is designedto investigate the Sentinel Lymph Node (SLN) detection rate in breast cancer for different biological characteristics.Material and Methods: Patients on whom we performed the methylene blue method alone were named as Group I, radiocolloid substancemethod alone as Group II and both methylene blue and radiocolloid method as Group III.
💡
Conclusion & Impact:The results of biological tumor characteristics and characteristicsof the patients on different SLN biopsy techniques were investigated.Results: The overall SLN detecting success rate was 83.3%.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

ABSTRACTObjective: Breast cancer subtypes are used as prognostic and predictive factors considering the genomic profile of the disease. This study is designedto investigate the Sentinel Lymph Node (SLN) detection rate in breast cancer for different biological characteristics.Material and Methods: Patients on whom we performed the methylene blue method alone were named as Group I, radiocolloid substancemethod alone as Group II and both methylene blue and radiocolloid method as Group III. The results of biological tumor characteristics and characteristicsof the patients on different SLN biopsy techniques were investigated.Results: The overall SLN detecting success rate was 83.3%. When considered for each group, success rate was 80% for group I, 84.9% for groupII and 90.6% for group III. While a success rate of 94.6% was achieved with radiocolloid only in the patients in Luminal A and B subgroup, 90%success rate was achieved in Her2 (+) and triple negative (TN) patients with combined method.Conclusion: While successful results could be achieved by using radiocolloid substances alone in patients with Luminal A and B subtypes, combinedmethods should be used in HER2 (+) and TN patients

🔖

Cite This Article

DOĞAN, L., AKGÜL, G. G., ÇOLAKOĞLU, M. K., GÜVEN, E., GÜLÇELİK, M. A. (2022). Biological Subtypes of Breast Cancer and Sentinel Lymph Node Biopsy. European Journal of Breast Health, Cilt: 14 - Sayı: 2, 100–104. https://ajindex.com/articles/510854

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. He PS, Li F, Li GH, Guo C, Chen TJ. The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review. BMC Cancer 2016
  2. (PMID: 26883751)[CrossRef ] La Verde N, Biagioli E, Gerardi C, Cordovana A, Casiraghi C, Floriani I, Bernardin E, Farina G, DiCosimo S, Dazzani MC, Gherardi G. Role of patient and tumor characteristics in sentinel lymph node metastasis in patients with luminal early breast cancer: an observational study. Springerplus 2016
  3. (PMID: 26885467) [CrossRef ] Morrow M, Rademaker AW, Bethke KP, Talamonti MS, Dawes LG, Clauson J, Hansen N. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery 1999
  4. (PMID: 10520920) [CrossRef ] Marchal F, Rauch P, Morel O, Mayer JC, Olivier P, Leroux A, Verhaeghe JL, Guillemin F. Results of preoperative lymphoscintigraphy for breast cancer are predictive of identification of axillary sentinel lymph nodes. World J Surg 2006
  5. (PMID: 16369717) [CrossRef ] Miner TJ, Shriver CD, Jaques DP, Maniscalco-Theberge ME, Krag DN. Sentinel lymph node biopsy for breast cancer: the role of previous biopsy on patient eligibility. Am Surg 1999
  6. (PMID: 10366201) Koizumi M, Nomura E, Yamada Y, Takiguchi T, Tanaka K, Yoshimoto M, Makita M, Sakamoto G, Kasumi F, Ogata E. Sentinel node detection using 99mTc-rhenium sulphide colloid in breast cancer patients: evaluation of 1 dayand 2 day protocols, and a dose-finding study. Nucl Med Commun 2003
  7. (PMID: 12766602) [CrossRef ] Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S, Beitsch P. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998
  8. (PMID: 9753708) [CrossRef ] Cox CE, Dupont E, Whitehead GF, Ebert MD, Nguyen K, Peltz ES, Peckham D, Cantor A, Reintgen DS. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast J 2002
  9. (PMID: 11896753) [CrossRef ] Chagpar AB, Martin RC, Scoggins CR, Carlson DJ, Laidley AL, El-Eid SE, McGlothin TQ, Noyes RD, Ley PB, Tuttle TM, McMasters KM. Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery 2005
  10. (PMID: 16003317) [CrossRef ] Chakera AH, Friis E, Hesse U, Al-Suliman N, Zerahn B, Hesse B. Factors of importance for scintigraphic non-vis